Compare Diamondback Energy Inc (FANG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Tango Therapeutics Inc. — how do they compare? Diamondback Energy Inc trades at $198 (market cap $55.49B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Diamondback Energy Inc is far larger — about 14.8× Tango Therapeutics Inc.'s market cap, and Diamondback Energy Inc pays a 2.22% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 70 Days and Tango Therapeutics Inc. for 0 Days on average.
| FANG | TNGX | |
|---|---|---|
Market Cap | $55.49B | $3.75B |
Volume | 2,752,760 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $213.69 | $32.90 |
52-Week Low | $137.29 | $7.50 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $67.65B | $2.77B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $197.51, up 1.23% with strong analyst support (90.57% buy rating) and a $232.54 consensus price target. Recent earnings beat expectations in Q1 and Q2 2026, while cash flow from operations improved to $8.76B in 2025. The stock shows bullish technical signals with support at $194 and resistance at $200, though RSI levels indicate potential overbought conditions.
FANG offers growth potential with rising revenue and operational efficiency, but faces risks from oil price volatility and declining profit margins. Institutional buying and positive Permian Basin developments support upside, while insider selling and competitive pressures warrant caution for investors seeking energy exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
